BioCryst Pharmaceuticals (NASDAQ: BCRX) — Company Overview, News & Financial Data
BioCryst Pharmaceuticals develops treatments for rare diseases, focusing on novel therapies in unmet medical needs.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals (NASDAQ:BCRX) specializes in the discovery, development, and commercialization of treatments for rare and serious diseases. This biotech firm focuses on developing novel therapies that target unmet medical needs, particularly in the areas of hereditary angioedema, autoimmune diseases, and viral infections. An integral part of their operations includes leveraging their unique drug discovery platform to advance a pipeline of promising treatment candidates. BioCryst's commitment to innovation and patient care drives its objective to provide effective solutions that can significantly improve the quality of life for patients dealing with challenging medical conditions.
Snapshot
Operations
Products and/or services of BioCryst Pharmaceuticals
- ORLADEYO® (berotralstat), a once-daily oral therapy preventing attacks in hereditary angioedema (HAE) patients.
- RAPTIVA® (rapivab), an antiviral treatment for influenza.
- PERAMIVIR, an injectable drug to treat influenza in adults.
- ALPIVAB™, a treatment for hospitalized patients with COVID-19.
- GALIDESIVIR, an antiviral in development for hemorrhagic fever viruses and coronaviruses.
BioCryst Pharmaceuticals executive team
- Charles K. GayerCEO, President & Director
- Babar GhiasCFO & Head of Corporate Development
- Alane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary
- John RueschChief Technical Operations Officer
- David W. JenkinsChief Scientific Officer
- Nick WilderManager of Investor Relations
- Stephanie AngeliniChief People Officer & Communications Officer
- William P. SheridanChief Development Officer
- Yarlagadda S. BabuChief Discovery Officer
- Jinky Ang RosselliChief Data Innovation Officer
Latest news about BioCryst Pharmaceuticals
Key financials
Reported results for BioCryst Pharmaceuticals, in USD.
- Market cap
- 2.1B
- Revenue (TTM)
- 940.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.4
- Dividend yield
- —
- Profit margin
- -40.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 874.8M | 341M | 263.9M | |
| 450.7M | -2.5M | -88.9M | |
| 331.4M | -103.7M | -226.5M | |
| 270.8M | -148.4M | -247.1M |